

in part, as "Norco Castor Oil," which act resulted in the article being adulterated and misbranded as described below.

In addition, between 1-15-57 and 1-24-57, the defendant caused to be introduced into interstate commerce, at Los Angeles, Calif., for delivery to Phoenix, Ariz., a quantity of an article labeled, in part, "Enterprise Solution of Hydrogen Peroxide U.S.P. 10 Volume $\frac{1}{4}$ Lb. (4 Oz. Av.) Enterprise Drug & Chemical Company Los Angeles, Calif.," which was adulterated as described below.

CHARGE: *Castor oil.* 501(d) (2)—turpentine had been substituted for *castor oil*, which the article was represented to be; 502(a)—the label statement "Castor Oil" was false and misleading; 502(i) (3)—the article was turpentine, and it was offered for sale under the name of another drug, namely, *castor oil*; and 502(j)—the article was dangerous to health when used in the dosage prescribed, recommended, and suggested in its labeling, namely, "Dose: Children, one to two teaspoonfuls. Adults, one to two tablespoonfuls."

Hydrogen peroxide solution. 501(b)—the quality and purity of the article fell below the standard for *hydrogen peroxide solution* set forth in the United States Pharmacopeia since the article contained isopropyl alcohol, which is not permitted in such standard.

PLEA: Guilty.

DISPOSITION: 4-21-58. \$1,500 fine.

NEW DRUGS SHIPPED WITHOUT EFFECTIVE APPLICATION

5482. Royal jelly capsules and royal jelly cream (2 seizure actions). (F.D.C. Nos. 41270, 41271. S. Nos. 73-114/7 M.)

QUANTITY: 71 btls., each containing 18 50-mg. capsules; 50 btls., each containing 60 50-mg. capsules; 24 btls., each containing 100 50-mg. capsules; 41 btls., each containing 15 75-mg. capsules; 30 btls., each containing 30 75-mg. capsules; 19 btls., each containing 15 125-mg. capsules; and 20 btls., each containing 30 125-mg. capsules, of *royal jelly*; and 43 1-oz. jars and 16 2-oz. jars of *royal jelly cream*, at Denver, Colo.

SHIPPED: Between 8-30-57 and 10-24-57, from Bayonne, N.J., by Continental Honey Products, Inc.

LABEL IN PART: (Btl.) "Imperial Royal Jelly Capsules * * * Continental Honey Products, Inc., Dist. N.Y."; (jar) "Imperial Royal Jelly Cream Continental Honey Products, Inc., Dist. N.Y." and "Imperial Royal Jelly Cream Queen Bee Royal Jelly and Lecithin."

ACCOMPANYING LABELING: Circulars entitled "Facing New Horizons With Imperial Royal Jelly."

LIBELED: 12-12-57, Dist. Colo.

CHARGE: 502(a)—the labeling accompanying the articles, when shipped, contained false and misleading representations that the articles would cure the ill, aid in the treatment of cancer, lengthen life, be beneficial in sexual deficiencies and ailments, be effective in the treatment of diseases of children, and increase intellectual activity; and that they were effective in treating liver ailments, arthritis, leukemia, and ulcers; and 505(a)—the articles were new drugs within the meaning of the law, and applications filed pursuant to the law were not effective with respect to the drugs.

DISPOSITION: 2-12-58. Default—a portion of the articles was delivered to the Food and Drug Administration, and the remainder was destroyed.